Inventaire - i tuoi amici e le tue comunità sono la tua biblioteca

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection

autore

Caroline M Perry

pubblicato in: Drugs

data di pubblicazione: 2010-06-01

argomento principale: HIV

Cita articoli 36

Data

Titolo

Autori

2010-02-11

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

Anne-Geneviève Marcelin, Christine Katlama, Sidonie Lambert-Niclot, Marc-Antoine Valantin, Slim Fourati, Marc Wirden, Cathia Soulié, Roland Tubiana, Isabelle Malet
2010-03-01

Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?

Paul E Sax
2010-03-01

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

Nathan Clumeck, Michael Saag, Andrzej Horban, Sharon Walmsley, Prudence Ive, Margaret Tawadrous
2010-04-01

Are the proposed env mutations actually associated with resistance to maraviroc?

Annalisa Saracino, Laura Monno, Gaetano Brindicci, Gioacchino Angarano
2010-03-01

A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals

Jeremy Chancellor, William G Powderly
2010-01-01

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir

Paul Glue
2009-04-18

Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients

Linos Vandekerckhove
2009-01-01

Novel targets for antiretroviral therapy: clinical progress to date

Mark Holodniy
2009-03-03

Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists

Natalia Chueca, Eva Poveda, Antonio Aguilera, Javier Rodríguez, Vicente Soriano, Juan González-Lahoz, Eduardo Seclén
2009-11-01

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients

Victoria Watson
2009-08-01

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women

Angela D. M. Kashuba
2009-06-01

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

Gerd Fätkenheuer, Nathan Clumeck, Bonaventura Clotet Sala, Michael Saag
2009-01-01

Drug interactions with new and investigational antiretrovirals
2008-04-01

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
2008-10-01

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

Gerd Fätkenheuer, Pablo Tebas, Adriano Lazzarin, Bernard Hirschel, Tomasz Smiatacz, Michael Saag, François Raffi
2008-08-01

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

Julio Montaner, Joseph J Eron, Robert T. Schooley, Scott M. Hammer, Peter Reiss, Sharon Walmsley, Margaret A Fischl
2008-10-01

Maraviroc for previously treated patients with R5 HIV-1 infection

Nathan Clumeck, Bonaventura Clotet Sala, Tomasz Smiatacz, Andrzej Horban
2008-10-01

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.

Robert L. Murphy, Anne-Geneviève Marcelin, Sidonie Lambert-Niclot, Christine Katlama, Anne Simon, Cathia Soulié, Roland Tubiana, Isabelle Malet
2008-04-01

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers
2008-10-01

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

Jane Anderson, Marta Boffito, Deenan Pillay, Andrew N Phillips
2008-10-01

A new class of anti-HIV therapy and new challenges
2008-04-01

Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers
2008-07-01

Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents
2008-06-01

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection

Carlo Federico Perno, Mauro Schechter
2008-04-01

A review of the clinical pharmacology of maraviroc. Introduction

Marta Boffito
2008-03

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
2008-04-10

Maraviroc: in vitro assessment of drug-drug interaction potential
2008-04-01

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
2007-01-01

Maraviroc

Gillian M Keating
2007-10-01

Genotypic coreceptor analysis
2006-12-20

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
2006-05-01

Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists

Articolo - wd:Q37762248

Benvenuto su Inventaire

la biblioteca dei tuoi amici e della tua comunità

ulteriori informazioni